PMID- 34194545
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 22
IP  - 2
DP  - 2021 Aug
TI  - Clinical relevance of donor-specific human leukocyte antigen antibodies after 
      pediatric liver transplantation.
PG  - 867
LID - 10.3892/etm.2021.10299 [doi]
LID - 867
AB  - Donor-specific human leukocyte antigen (HLA) antibodies (DSAs) have a significant 
      role in graft survival after pediatric liver transplantation. To understand the 
      significance of DSAs, a retrospective cohort study of 48 pediatric liver 
      transplant recipients with posttransplant serum samples that were analyzed for 
      DSAs was performed. According to their test results, the recipients were divided 
      into a DSA-positive group and a DSA-negative group. Postoperative liver 
      transplantation biopsies were performed in patients with abnormal liver function. 
      The liver condition and prognosis of the recipients were recorded, and their 
      association was analyzed. A total of 48 recipients were followed up for 2.7+/-0.8 
      years. DSA positivity was detected in 10 cases (20.8%). One case was positive for 
      HLA class I and HLA class II antibodies, whereas 9 cases were positive for HLA 
      class II antibodies, and the gene loci were HLA-DR and/or DQ. Antibody-mediated 
      rejection (AMR) occurred in four of 10 patients in the DSA-positive group. Liver 
      function was abnormal in 3 of 38 cases in the DSA-negative group. Multivariate 
      analysis revealed that DSA positivity was an independent risk factor for liver 
      insufficiency and long-term survival of recipients. In addition, Kaplan-Meier 
      survival analysis demonstrated that there were significant differences in the 
      survival of graft recipients between the DSA-positive group and the DSA-negative 
      group (P<0.05). The positivity of DSAs after pediatric liver transplantation was 
      closely related to the occurrence of AMR. These results suggested that DSAs 
      should be routinely monitored post-operatively, and that DSA-positive recipients 
      should be screened as soon as possible and given appropriate treatment.
CI  - Copyright: (c) Liu et al.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Blood Transfusion, Tianjin First Central Hospital, Tianjin 300192, 
      P.R. China.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Transplantation Surgery, Tianjin First Central Hospital, Tianjin 
      300192, P.R. China.
FAU - Xiao, Yan-Li
AU  - Xiao YL
AD  - Department of Blood Transfusion, Tianjin First Central Hospital, Tianjin 300192, 
      P.R. China.
FAU - Liu, Chun
AU  - Liu C
AD  - Department of Blood Transfusion, Tianjin First Central Hospital, Tianjin 300192, 
      P.R. China.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Transplantation Surgery, Tianjin First Central Hospital, Tianjin 
      300192, P.R. China.
FAU - Li, Dai-Hong
AU  - Li DH
AD  - Department of Blood Transfusion, Tianjin First Central Hospital, Tianjin 300192, 
      P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20210613
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC8237393
OTO - NOTNLM
OT  - antibody-mediated rejection
OT  - donor-specific human leukocyte antigen antibodies
OT  - incidence of liver events
OT  - long-term survival
OT  - pediatric liver transplantation
COIS- The authors declare that they have no competing interests.
EDAT- 2021/07/02 06:00
MHDA- 2021/07/02 06:01
PMCR- 2021/06/13
CRDT- 2021/07/01 06:57
PHST- 2019/09/03 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2021/07/01 06:57 [entrez]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2021/07/02 06:01 [medline]
PHST- 2021/06/13 00:00 [pmc-release]
AID - ETM-0-0-10299 [pii]
AID - 10.3892/etm.2021.10299 [doi]
PST - ppublish
SO  - Exp Ther Med. 2021 Aug;22(2):867. doi: 10.3892/etm.2021.10299. Epub 2021 Jun 13.